Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aurora Biosciences (ABSC) -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (228)	12/8/1999 2:25:00 PM
From: tuck	Read Replies (1) \| Respond to of 359

Vector1, Shortly thereafter, we get news that ABSC's second module has been validated by Parke-Davis, triggering a milestone payment. go2net.newsalert.com This is a watershed moment, IMHO. This second module posed tougher engineering challenges than did other modules, as I understand it. Thus validation by this customer is key, as it validates ABSC's positive fundamental outlook in terms of future earnings from this product. Even if senior indexes correct, ABSC should do well. Yeah, I'm liking this trade, too. I think I might hold for some time. Hey, I just came up with this idea: wouldn't it be good for ABSC to partner with one of those companies that has quality libraries? Those selling chips or screening sytems might not want to partner in this way. Pure plays such as PCOP might be quite willing. What do you think of this idea? Should it be proposed to ABSC's management? What companies woud be good candidates? Cheers, Tuck